Patent expiry and costs for anti-cancer medicines for clinical use

GaBI Journal

Volumn 6, Issue 3, 2017, Pages 105-106

  Godman, Brian ^a,b,c   Wild, Claudia ^d   Haycox, Alan ^c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Cancer medicines; Generics; Health gain; Prices; Tyrosine kinase inhibitors (TKI)

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DASATINIB; EVEROLIMUS; GEFITINIB; GENERIC DRUG; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER MORTALITY; CIVIL RIGHTS; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; EUROPE; EXPIRATION DATE; HEALTH CARE ACCESS; HUMAN; NOTE; OVERALL SURVIVAL; PATENT; UNITED STATES;

EID: 85033362837     PISSN: 20336403     EISSN: 20336772     Source Type: Journal    
DOI: 10.5639/gabij.2017.0603.021     Document Type: Note

References (19)

1. Venkatesan S, Lamfers M, Leenstra S, Vulto AG. Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and the US. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(2):89-96. doi:10.5639/gabij.2017.0602.016
2. European Parliament. Godman B, Oortwijn W, de Waure C, Mosca I, Puggina A, Specchia ML, et al. Links between pharmaceutical R&D models and access to affordable medicines. A study for the ENVI Committee [homepage on the Internet]. [cited 2017 Mar 15]. Available from: http://www.europarl.europa.eu/RegData/etudes/STUD/2016/587321/IPOL_STU(2016)587321_EN.pdf
3. Malmström RE, Godman BB, Diogene E, Baumgärtel C, Bennie M, Bishop I, et al. Dabigatran-a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39
4. Kesselheim AS, Myers JA, Solomon DH, Winkel-mayer WC, Levin R, Avorn J. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012;7(2):e31894
5. Top 50 pharmaceutical products by global sales. PMLiVE
6. Hill A, Redd C, Gotham D, Erbacher I, Meldrum J, Harada R. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ Open. 2017;7(1):e011965
7. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15(3):e112-8
8. Bach PB. Reforming the payment system for medical oncology. JAMA. 2013;310(3):261-2
9. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139-62
10. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol. 2013;31(28):3600-4
11. Grössmann N, Wild C. Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? ESMO Open. 2017;1:e000125. doi:10.1136/esmoopen-2016-000125
12. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996-1000
13. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-42
14. World Health Organization. Hoen Et. Access to cancer treatment. A study of medicine pricing issues with recommendations for improving access to cancer medication [homepage on the Internet]. [cited 2017 Mar 15]. Available from: http://apps.who.int/medicinedocs/documents/s21758en/s21758en.pdf
15. Ghinea N, Kerridge I, Lipworth W. If we don't talk about value, cancer drugs will become terminal for health systems. The Conversation. 26 July 2015
16. Haycox A. Why cancer? Pharmacoeconomics. 2016;34(7):625-7
17. Wild C, Grössmann N, Bonanno PV, Bucsics A, Furst J, Garuoliene K, et al. Utilisation of the ESMO-MCBS in practice of HTA. Ann Oncol. 2016;27(11):2134-6
18. Matusewicz W, Godman B, Pedersen HB, Fürst J, Gulbinovic J, Mack A, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755-8
19. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. EMiNet, Brussels, Belgium. LSE Research Online. 2013